Biogen Idec, Inc. (Massachusetts) AVONEX(R), The Most Prescribed Multiple Sclerosis Therapy Worldwide, Celebrates 10th Anniversary

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 19, 2006--Biogen Idec (NASDAQ:BIIB - News) today marks the 10th anniversary of AVONEX® (Interferon beta-1a), the most prescribed multiple sclerosis (MS) therapy worldwide, as the company's CEO James Mullen, rings the NASDAQ Stock Market Opening Bell. AVONEX, manufactured by Biogen Idec, was approved for relapsing forms of MS by the U.S. Food and Drug Administration (FDA) on May 17, 1996. Shortly after its introduction in the U.S., it became the number one prescribed therapy in MS. Today more than 130,000 patients worldwide choose AVONEX to treat their MS.

Back to news